MCID: DBT007
MIFTS: 32

Diabetic Cataract malady

Categories: Eye diseases

Aliases & Classifications for Diabetic Cataract

Aliases & Descriptions for Diabetic Cataract:

Name: Diabetic Cataract 12 52 14 69
Cataract - Diabetic 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13328
ICD9CM 35 366.41
ICD10 33 H28.0
UMLS 69 C0011876

Summaries for Diabetic Cataract

MalaCards based summary : Diabetic Cataract, also known as cataract - diabetic, is related to turner syndrome and premature aging okamoto type. An important gene associated with Diabetic Cataract is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways is Celecoxib Pathway, Pharmacodynamics. The drugs Isosorbide Dinitrate and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include eye.

Related Diseases for Diabetic Cataract

Diseases related to Diabetic Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 26)
id Related Disease Score Top Affiliating Genes
1 turner syndrome 10.7
2 premature aging okamoto type 10.7
3 cataract 10.6
4 mucopolysaccharidosis 10.2 AKR1B1 VEGFA
5 angular blepharoconjunctivitis 10.1 SERPINF1 VEGFA
6 multilocular clear cell renal cell carcinoma 10.1 SERPINF1 VEGFA
7 adult infiltrating astrocytic neoplasm 10.1 SERPINF1 VEGFA
8 benign familial neonatal epilepsy 10.1 SERPINF1 VEGFA
9 pyriform sinus cancer 10.1 SERPINF1 VEGFA
10 ectodermal dysplasia bartalos type 10.1 SERPINF1 VEGFA
11 scar contracture 10.1 SERPINF1 VEGFA
12 subdural empyema 10.0 SERPINF1 VEGFA
13 anterograde amnesia 10.0 SERPINF1 VEGFA
14 vernal conjunctivitis 10.0 AKR1B1 SERPINF1 VEGFA
15 citrullinemia, type ii, neonatal-onset 10.0 AKR1B1 SERPINF1 VEGFA
16 epidermolysis bullosa simplex, sutosomal recessive 2 10.0 SERPINF1 VEGFA
17 sacrococcygeal teratoma 10.0 CAT VEGFA
18 conjugate gaze palsy 10.0 CRYGS VEGFA
19 prostate disease 10.0 CRYGS VEGFA
20 pseudopterygium 9.9 AKR1B1 CRYGS VEGFA
21 pseudo-gaucher disease 9.8 CACNA1C CAT
22 neuropathy 9.7
23 retinitis 9.5
24 hyperglycemia 9.5
25 obesity 9.5
26 congenital toxoplasmosis 8.8 AKR1B1 CACNA1C CAT CRYGS NIN PPARD

Comorbidity relations with Diabetic Cataract via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetic Polyneuropathy
Heart Disease Hypertension, Essential
Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 7

Graphical network of the top 20 diseases related to Diabetic Cataract:



Diseases related to Diabetic Cataract

Symptoms & Phenotypes for Diabetic Cataract

Drugs & Therapeutics for Diabetic Cataract

Drugs for Diabetic Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
2
Nitric Oxide Approved Phase 4 10102-43-9 145068
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
4
Ketorolac Approved Phase 4,Phase 2 74103-06-3, 66635-83-4 3826
5
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
6
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
7
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Early Phase 1 67-73-2 6215
8
Nepafenac Approved Phase 4,Phase 3,Phase 2 78281-72-8 151075
9
Bromfenac Approved July 1997 Phase 4,Phase 3 91714-94-2 60726
10 diuretics Phase 4
11 Isosorbide Phase 4
12 isosorbide-5-mononitrate Phase 4
13 Natriuretic Agents Phase 4
14 Nitric Oxide Donors Phase 4
15 Vasodilator Agents Phase 4
16 Antiemetics Phase 4,Phase 3,Phase 2
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
19 Autonomic Agents Phase 4,Phase 3,Phase 2
20 BB 1101 Phase 4,Phase 3,Phase 2
21 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2
22 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
24 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
30
protease inhibitors Phase 4,Phase 3,Phase 2
31 Analgesics Phase 4,Phase 3,Phase 2
32 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2
35 Cyclooxygenase Inhibitors Phase 4
36 Ketorolac Tromethamine Phase 4,Phase 2
37 Anti-Asthmatic Agents Phase 4
38 Anti-Bacterial Agents Phase 4
39 Antibiotics, Antitubercular Phase 4
40 Anti-Infective Agents Phase 4
41 Betamethasone benzoate Phase 4
42 Betamethasone sodium phosphate Phase 4
43 Betamethasone Valerate Phase 4 2152-44-5
44 Betamethasone-17,21-dipropionate Phase 4
45 Homatropine Phase 4
46 Norgestimate, ethinyl estradiol drug combination Phase 4
47 Parasympatholytics Phase 4
48 Respiratory System Agents Phase 4,Phase 3,Phase 2
49 Topoisomerase Inhibitors Phase 4
50 Ophthalmic Solutions Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 73)
id Name Status NCT ID Phase
1 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
2 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4
3 Protein Profile of Immunoregulatory Factors in Diabetic Cataract Completed NCT01832311 Phase 4
4 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4
5 Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients Completed NCT02646072 Phase 4
6 Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification Completed NCT02089698 Phase 4
7 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4
8 Corneal Endothelial Changes Associated With Phacoemulsification in Diabetes Mellitus Type II Completed NCT01078103 Phase 4
9 Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Completed NCT01310127 Phase 4
10 Corneal Endothelial Cell Loss in Diabetes Type II During Cataract Surgery Suspended NCT00446277 Phase 4
11 Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial Unknown status NCT00370422 Phase 3
12 Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema Unknown status NCT00370669 Phase 3
13 Nepafenac Once Daily for Macular Edema - Study 1 Completed NCT01853072 Phase 3
14 Nepafenac Once Daily for Macular Edema - Study 2 Completed NCT01872611 Phase 3
15 The Effect of Intravitreal Ozurdex on DME After Cataract Surgery Completed NCT01748487 Phase 3
16 Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) Completed NCT00542178 Phase 3
17 PRevention of Macular EDema After Cataract Surgery Completed NCT01774474 Phase 3
18 Bevacizumab Versus Ranibizumab for Diabetic Retinopathy Completed NCT00545870 Phase 3
19 Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO) Completed NCT00167518 Phase 2, Phase 3
20 A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma Completed NCT00434161 Phase 3
21 Macular Edema Incidence/Severity Reduction With Nevanac Terminated NCT00939276 Phase 3
22 The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy Unknown status NCT00849537 Phase 1, Phase 2
23 Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery Unknown status NCT00801450 Phase 1, Phase 2
24 Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery Completed NCT01284478 Phase 2
25 A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients Completed NCT00782717 Phase 2
26 Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS) Completed NCT01030601 Phase 2
27 A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema Completed NCT00369486 Phase 2
28 A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus Completed NCT01673191 Phase 2
29 A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema Completed NCT00369863 Phase 2
30 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery Recruiting NCT01988246 Phase 1, Phase 2
31 Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Recruiting NCT02486484 Phase 2
32 Pain and Visual Outcome in Intravitreal Bevacizumab Injection Enrolling by invitation NCT02790775 Phase 2
33 Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics Terminated NCT00346983 Phase 1, Phase 2
34 Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery Completed NCT01069341 Phase 1
35 Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders Completed NCT00101764 Phase 1
36 Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema Completed NCT00826618 Phase 1
37 Triple Therapy for Diffuse Diabetic Macular Edema Unknown status NCT01218750
38 Intravitreal Bevacizumab for Retinal Disorders Unknown status NCT00403026
39 Changes in Vitreous Temperature During Phacoemulsification Unknown status NCT01568242
40 Preoperative Topic Diclofenac as a Prevention of Postoperative Macular Edema in Patients With Diabetic Retinopathy Completed NCT01694212
41 Triamcinolone vs. Laser for Diabetic Macular Edema Completed NCT00229931
42 Long Term Follow-Up of Diabetic Retinopathy Completed NCT00001395
43 Evaluation of Vitrectomy for Diabetic Macular Edema Completed NCT00709319
44 Corneal Changes in Diabetics After Phacoemulsification Completed NCT02548273
45 Evaluation of Posterior Capsule Opacification in Eyes With Diabetes Mellitus Completed NCT01480934
46 Serum and Intraocular Levels of Erythropoietin and VEGF in Type 2 Diabetes Patients With Proliferative Retinopathy Completed NCT01871207
47 Phacoemulsification and 25 Gauge (25G) Vitrectomy Versus Phacoemulsification Only in Idiopathic Epiretinal Membranes Completed NCT01771939
48 Impact of C3F8 or SF6 Use and Length of Face-down Positioning (7 vs 14 Days Respectively) in Macular Hole Surgery Completed NCT02073266
49 A Pilot Study Investigating the Impact of Different IOL Designs on Subjective 2D and 3D Image Quality Completed NCT02409641
50 Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study Completed NCT00286507

Search NIH Clinical Center for Diabetic Cataract

Genetic Tests for Diabetic Cataract

Anatomical Context for Diabetic Cataract

MalaCards organs/tissues related to Diabetic Cataract:

39
Eye

Publications for Diabetic Cataract

Articles related to Diabetic Cataract:

(show top 50) (show all 109)
id Title Authors Year
1
Potential of CeCl3@mSiO2 nanoparticles in alleviating diabetic cataract development and progression. ( 28065730 )
2017
2
Investigation of synergistic mechanism and identification of interaction site of aldose reductase with the combination of gigantol and syringic acid for prevention of diabetic cataract. ( 27520089 )
2016
3
Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity. ( 27372406 )
2016
4
DL-3-n-butylphthalide delays the onset and progression of diabetic cataract by inhibiting oxidative stress in rat diabetic model. ( 26759189 )
2016
5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract. ( 27140653 )
2016
6
Inhibitory Effect of Crocin(s) on Lens I+-Crystallin Glycation and Aggregation, Results in the Decrease of the Risk of Diabetic Cataract. ( 26821002 )
2016
7
Featured Article: Inhibition of diabetic cataract by glucose tolerance factor extracted from yeast. ( 26825353 )
2016
8
Structure-Activity Relationship Study Reveals Benzazepine Derivatives of Luteolin as New Aldose Reductase Inhibitors for Diabetic Cataract. ( 27396410 )
2016
9
A Genome-Wide Association Study Provides New Evidence That CACNA1C Gene is Associated With Diabetic Cataract. ( 27124316 )
2016
10
Calpain and Caspase-12 Expression in Lens Epithelial Cells of Diabetic Cataracts. ( 27130368 )
2016
11
Grape seed extract and Zinc containing nutritional food supplement delays onset and progression of Streptozocin-induced diabetic cataract in Wistar rats. ( 25892780 )
2015
12
Differential Protein Expression between Type 1 Diabetic Cataract and Age-Related Cataract Patients. ( 26333124 )
2015
13
Protective effect of resveratrol on lens epithelial cell apoptosis in diabetic cataract rat. ( 25902031 )
2015
14
Synthesis and Biological Evaluation of Novel Gigantol Derivatives as Potential Agents in Prevention of Diabetic Cataract. ( 26517726 )
2015
15
Corneal Bullous Epithelial Detachment in Diabetic Cataract Surgery. ( 26002007 )
2015
16
Levels of Selected Aqueous Humor Mediators (IL-10, IL-17, CCL2, VEGF, FasL) in Diabetic Cataract. ( 25314260 )
2014
17
Inhibition of diabetic-cataract by vitamin K1 involves modulation of hyperglycemia-induced alterations to lens calcium homeostasis. ( 25257692 )
2014
18
Expression of p53 and caspase-8 in lens epithelial cells of diabetic cataract. ( 24957431 )
2014
19
Preventive effect of Zea mays L. (purple waxy corn) on experimental diabetic cataract. ( 24527449 )
2014
20
Retraction. Activation of aldose reductase by interaction with tubulin and involvement of this mechanism in diabetic cataract formation. Diabetes. 10 April 2014 [Epub ahead of print]. DOI: 10.2337/db13-1265. ( 24722247 )
2014
21
Effects of two antioxidants; I+-lipoic acid and fisetin against diabetic cataract in mice. ( 25488016 )
2014
22
Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats. ( 23671855 )
2013
23
Novel susceptibility genes associated with diabetic cataract in a Taiwanese population. ( 23137000 )
2013
24
Inhibition of protein glycation by procyanidin-B2 enriched fraction of cinnamon: delay of diabetic cataract in rats. ( 24136906 )
2013
25
Inhibition of aldose reductase by Aegle marmelos and its protective role in diabetic cataract. ( 23827758 )
2013
26
Early phacoemulsification in diabetic cataract for early recognition and management of diabetic macular oedema. ( 23763799 )
2013
27
GP-1447, an inhibitor of aldose reductase, prevents the progression of diabetic cataract in rats. ( 22687477 )
2012
28
Na+/H+-exchanger-1 inhibition counteracts diabetic cataract formation and retinal oxidative-nitrative stress and apoptosis. ( 22407349 )
2012
29
Promoter demethylation of Keap1 gene in human diabetic cataractous lenses. ( 22683333 )
2012
30
Syringic Acid Extracted from Herba dendrobii Prevents Diabetic Cataract Pathogenesis by Inhibiting Aldose Reductase Activity. ( 23365598 )
2012
31
Topical metal chelation therapy ameliorates oxidation-induced toxicity in diabetic cataract. ( 21271438 )
2011
32
Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract. ( 21753902 )
2011
33
Diabetic cataract-pathogenesis, epidemiology and treatment. ( 20634936 )
2010
34
Relationship between Pentosidine and Pyridinoline Levels in Human Diabetic Cataract Lenses. ( 21103032 )
2010
35
Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats. ( 20806076 )
2010
36
Elevated Expression of indoleamine 2,3-dioxygenase (IDO) and accumulation of kynurenic acid in the pathogenesis of STZ-induced diabetic cataract in Wistar rats. ( 19373575 )
2009
37
Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats. ( 19898641 )
2009
38
Influence of selected angiotensin-converting enzyme inhibitors on alloxan-induced diabetic cataract in rabbits. ( 19865050 )
2009
39
Delay of diabetic cataract in rats by the antiglycating potential of cumin through modulation of alpha-crystallin chaperone activity. ( 18789666 )
2009
40
Potential use of hirudin in diabetic cataract: a study of galactose mediated human lens epithelial cells injury. ( 18400216 )
2008
41
Changes in erythrocyte glucose-6-phosphate dehydrogenase (G6PD) and reduced glutathione (GSH) activities in the development of senile and diabetic cataracts. ( 19058613 )
2008
42
Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats. ( 18490958 )
2008
43
Efficacy of alpha-lipoic acid against diabetic cataract in rat. ( 17295134 )
2007
44
Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. ( 17679931 )
2007
45
Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis. ( 16540489 )
2006
46
Acute irreversible diabetic cataract in adolescence: a case report. ( 15877100 )
2006
47
Synergism between phospholipase D2 and sorbitol accumulation in diabetic cataract formation through modulation of Na,K-ATPase activity and osmotic stress. ( 16797533 )
2006
48
Role of anti-oxidant enzymes superoxide dismutase and catalase in the development of cataract : study of serum levels in patients with senile and diabetic cataracts. ( 17240813 )
2006
49
Antioxidant markers in human senile and diabetic cataractous lenses. ( 17007750 )
2006
50
Correlation between adult diabetic cataracts and red blood cell aldose reductase levels. ( 16639016 )
2006

Variations for Diabetic Cataract

Expression for Diabetic Cataract

Search GEO for disease gene expression data for Diabetic Cataract.

Pathways for Diabetic Cataract

Pathways related to Diabetic Cataract according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.39 CACNA1C VEGFA

GO Terms for Diabetic Cataract

Biological processes related to Diabetic Cataract according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.46 AKR1B1 CAT PPARD VEGFA
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.37 CAT PPARD
3 response to activity GO:0014823 9.32 CAT PPARD
4 positive regulation of cell division GO:0051781 9.26 CAT VEGFA
5 response to vitamin A GO:0033189 8.96 CAT PPARD
6 kidney development GO:0001822 8.8 CAT SERPINF1 VEGFA

Sources for Diabetic Cataract

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....